Tubular brain tumor biopsy improves diagnostic yield for subcortical lesions
Molecular data has become an essential part of the updated World Health Organization (WHO) grading of central nervous system tumors. However, stereotactic needle biopsies provide only small volume specimens and limit the extent of histologic and molecular testing that can be performed. We assessed the use of a tubular retractor-based minimally invasive biopsy technique to provide improved tissue yield and diagnostic data compared to needle biopsy.
Eighteen patients underwent an open transtubular biopsy compared to 146 stereotactic biopsies during the years of 2010–2018.
Tubular biopsies resulted in a higher volume of tissue provided to the pathologist than needle biopsies (1.26 cm3 vs. 0.3 cm3; p < 0.0001). There was a higher rate of non-diagnostic sample with stereotactic compared to transtubular biopsy (13% vs. 0%; p = 0.13). Six patients who underwent stereotactic biopsy required reoperation for diagnosis, while no transtubular biopsy patient required reoperation in order to obtain a diagnostic specimen. Postoperative hematoma was the most common post-operative complication in both groups.
Stereotactic transtubular biopsies are a viable alternative to stereotactic needle biopsies with excellent rates of diagnostic success and acceptable morbidity relative to the needle biopsy technique. As molecular data begins to increasingly drive treatment decisions, additional biopsy techniques that afford large tissue volumes may be necessary to adapt to the new needs of pathologists and treating oncologists.
KeywordsStereotactic Tubular Biopsy Neurosurgery Complication Hemorrhage
The authors would like to acknowledge Debra D’Angelo for her contributions to the statistical analyses performed in this research.
Supplementary material video (MP4 19628 KB)
- 2.Krieger MD, Chandrasoma PT, Zee C-S, Apuzzo MLJ (1998) Role of stereotactic biopsy in the diagnosis and management of brain tumors. Semin Surg Oncol 14:13–25. https://doi.org/10.1002/(SICI)1098-2388(199801/02)14:1%3C13::AID-SSU3%3E3.0.CO;2-5 CrossRefGoogle Scholar
- 4.Reithmeier T, Lopez WO, Doostkam S et al (2013) Intraindividual comparison of histopathological diagnosis obtained by stereotactic serial biopsy to open surgical resection specimen in patients with intracranial tumours. Clin Neurol Neurosurg 115:1955–1960. https://doi.org/10.1016/j.clineuro.2013.05.019 CrossRefGoogle Scholar
- 6.Hall WA (1998) The safety and efficacy of stereotactic biopsy for intracranial lesions. Cancer 82:1749–1755. https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9%3C1756::AID-CNCR23%3E3.0.CO;2-2 CrossRefGoogle Scholar
- 12.Herrera SR, Shin JH, Chan M et al (2010) Use of transparent plastic tubular retractor in surgery for deep brain lesions: a case series. Surg Technol Int 19:47–50Google Scholar
- 22.Greenfield JP, Cobb WS, Tsouris AJ, Schwartz TH (2008) Stereotactic minimally invasive tubular retractor system for deep brain lesions. Neurosurgery 63:334–339. https://doi.org/10.1227/01.neu.0000334741.61745.72 (discussion 339–340)CrossRefGoogle Scholar
- 25.Kelly PJ (1989) Future perspectives in stereotactic neurosurgery: stereotactic microsurgical removal of deep brain tumors. J Neurosurg Sci 33:149–154Google Scholar
- 27.Moshel YA, Link MJ, Kelly PJ (2007) Stereotactic volumetric resection of thalamic pilocytic astrocytomas. Neurosurgery 61:66–75. https://doi.org/10.1227/01.neu.0000279725.13521.a3 (discussion 75)CrossRefGoogle Scholar
- 35.Bander ED, Jones SH, Kovanlikaya I, Schwartz TH (2016) Utility of tubular retractors to minimize surgical brain injury in the removal of deep intraparenchymal lesions: a quantitative analysis of FLAIR hyperintensity and apparent diffusion coefficient maps. J Neurosurg 124:1053–1060. https://doi.org/10.3171/2015.4.JNS142576 CrossRefGoogle Scholar
- 43.Favre J, Taha JM, Burchiel KJ (2002) An analysis of the respective risks of hematoma formation in 361 consecutive morphological and functional stereotactic procedures. Neurosurgery 50:48–56 (discussion 56–57)Google Scholar
- 46.Tourneau CL, Delord J-P, Gonçalves A et al (2015) Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 16:1324–1334. https://doi.org/10.1016/S1470-2045(15)00188-6 CrossRefGoogle Scholar